A Relative Bioavailability Study of HRS9531 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

September 4, 2023

Study Completion Date

September 4, 2023

Conditions

Type 2 Diabetes

Interventions

DRUG

HRS9531

Receive a single dose of HRS9531 of original formulation.

DRUG

HRS9531

Receive a single dose of HRS9531 of new formulation.

Trial Locations (1)

Central hospital affiliated to Shandong first mecical university, Jinan

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05893576 - A Relative Bioavailability Study of HRS9531 in Healthy Subjects | Biotech Hunter | Biotech Hunter